シンポジウム11：シヌクレイノパチーの病態・治療 update
シヌクレイノパチーのバイオマーカー
2020 年 37 巻 4 号 p. 626-628
詳細
2020 年 37 巻 4 号 p. 626-628
Clinicians need reliable diagnostic and prognostic biomarkers for synucleinopathies including Parkinson's disease. The diagnosis of Parkinson's disease mostly depends on clinical findings, and recent research identified that the potential diagnostic and prognostic value of CSF and blood biomarkers closely reflecting the pathophysiology of Parkinson's disease, such as α–synuclein. And recent research developed the detection methods based on amplification of synuclein seeds (e.g. RT–QuIC or PMCA). So we introduced that αSyn seeding activity may serve as a novel biomarker for antemortem diagnoses of PD and other synucleinopathies.
